United Therapeutics Corporation (UTHR) Stock Analysis

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $503.60
• Market Cap: $24.20B
• P/E Ratio: 17.89
• EPS: $29.91
• 52-Week High: $537.19
• 52-Week Low: $266.98

Market Sentiment

United Therapeutics Corporation currently has a Neutral sentiment score of 0.14.

About United Therapeutics Corporation

United Therapeutics Corporation (UTHR) is a pioneering biotechnology company dedicated to developing and commercializing groundbreaking therapies for patients suffering from chronic and life-threatening conditions, particularly targeting pulmonary hypertension and organ transplantation. Based in Silver Spring, Maryland, the company boasts a strong pipeline and innovative technologies that address critical unmet medical needs in the U.S. and worldwide. With a steadfast commitment to advancing ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for United Therapeutics Corporation and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does UTHR pay dividends?

United Therapeutics Corporation (UTHR) does not currently pay a regular dividend.

What is UTHR's P/E ratio?

United Therapeutics Corporation has a price-to-earnings (P/E) ratio of 17.89.

What is UTHR's market cap?

United Therapeutics Corporation (UTHR) has a market capitalization of $24.20B with a current stock price of $503.60.